Plasma marinobufagenin immunoreactivity in patients with chronic kidney disease: a case control study

Experimental data have shown increased plasma levels of marinobufagenin in kidney failure. In this case-controlled retrospective analysis, we evaluated plasma marinobufagenin immunoreactivity in hemodialysis patients compared with subjects with normal kidney function. Sixty-eight adult hemodialysis...

Full description

Saved in:
Bibliographic Details
Published in:American journal of physiology. Renal physiology 2018-09, Vol.315 (3), p.F637-F643
Main Authors: Piecha, Grzegorz, Kujawa-Szewieczek, Agata, Kuczera, Piotr, Skiba, Katarzyna, Sikora-Grabka, Ewelina, Więcek, Andrzej
Format: Article
Language:English
Subjects:
Aldosterone
Blood pressure
End-stage renal disease
Glomerular filtration rate
Hemodialysis
Immune system
Immunoreactivity
Kidney diseases
Plasma
Plasma levels
Renal failure
Citations: Items that this one cites
Items that cite this one
Online Access:Get full text
Tags: Add Tag
No Tags, Be the first to tag this record!
Description
Summary:Experimental data have shown increased plasma levels of marinobufagenin in kidney failure. In this case-controlled retrospective analysis, we evaluated plasma marinobufagenin immunoreactivity in hemodialysis patients compared with subjects with normal kidney function. Sixty-eight adult hemodialysis patients with chronic kidney disease (34 females and 34 males) as well as 68 age-, gender-, and blood pressure-matched subjects without chronic kidney disease were enrolled. Patients on stable hemodialysis regimen for at least 3 mo before the study were included. Exclusion criteria were: age
ISSN:1931-857X
1522-1466
DOI:10.1152/ajprenal.00046.2018